Work

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials

Year: 2019

Type: article

Abstract: 0.0137). Other adverse events were largely comparable. Overall, empirically designed DBL showed comparable clinical and microbiological responses across different Gram-negative species, and were significantly safer than BLAG. Therefore, DBL should be rationally optimized via the latest translational approaches, leveraging mechanistic insights and newer β-lactams for future evaluation in clinical trials.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.00425-19

Authors: Yuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, Alexandre P. Zavascki, Hsinyin Tsai, Xun Tao, Dhruvitkumar S. Sutaria, Arnold Louie, John D. Boyce, Deanna Deveson Lucas, Tae Hwan Kim, Brian T. Tsuji, Robert A. Bonomo, George L. Drusano, Jürgen B. Bulitta

Institutions: University of Florida, Universidade Federal do Rio Grande do Sul, Monash University, Daegu Catholic University, University at Buffalo, State University of New York, Louis Stokes Cleveland VA Medical Center, Case Western Reserve University

Language: English

Topic: Antibiotics Pharmacokinetics and Efficacy

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Institute of Allergy and Infectious Diseases

Awards: G1003374595, G1143233013, G2647071862, G3004358298, Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii, G636376783, Understanding B-Lactam Resistance in Acinetobacter baumannii

OpenAlex ID: W2939959611

FWCI: 2.221

Cites: 68

Cited by: 37

Related to: 10